Traws Pharma
TRAW
8 hedge funds and large institutions have $3.8M invested in Traws Pharma in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
2,389% more capital inflows, than outflows
Capital inflows: $4.74M | Capital outflows: $190K
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding
Funds holding: 4 → 8 (+4)
18.44% more ownership
Funds ownership: 2.35% → 20.79% (+18%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.43M |
| 2 |
Boxer Capital
San Diego,
California
|
+$1.14M |
| 3 |
Renaissance Technologies
New York
|
+$163K |
| 4 |
Eagle Global Advisors
Houston,
Texas
|
+$61.3K |
| 5 |
Alambic Investment Management
Belvedere,
California
|
+$40.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$102K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.8K |
| 3 |
Weiss Multi-Strategy Advisers
New York
|
-$20.4K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$14K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7K |
TRAW Hedge Fund Activity: Q3 2016 in Review
8 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2016, worth a combined $3.8M — up 341% from $861K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TRAW positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.43M. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $102K sold.
- 8 institutional investors held Traws Pharma (TRAW) as of Q3 2016, up from 4 in Q2 2016.
- Funds reported $3.8M of Traws Pharma stock for Q3 2016, up 341% quarter-over-quarter.
- 5 funds opened new Traws Pharma positions in Q3 2016 and 1 closed out, a net change of +4 holders.
- The largest Traws Pharma buyer in Q3 2016 was Sabby Management, an estimated $1.43M added.
- The largest Traws Pharma seller in Q3 2016 was Royal Bank of Canada, an estimated $102K sold.
Based on aggregated 13F filings for Q3 2016.